Exagen Inc.
Exagen (Nasdaq: XGN) is a medical technology company that develops and commercializes blood tests for diagnosing, prognosing and monitoring rheumatic and autoimmune diseases, including lupus and rheumatoid arthritis. Its AVISE® portfolio serves rheumatologists and other healthcare providers, with tests designed to… From the company’s description.
Over the twelve months to Jun 30, 2026, Exagen Inc. reported revenue of $71.12M, up 20.8% from a year earlier, and a net loss of $18.92M. Its operating margin was −18.6%, and operations used $6.50M in cash. In fiscal 2025, it reported revenue of $66.58M, up 19.7% from fiscal 2024, and a net loss of $19.95M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Exagen Inc. does
In the company’s own words
Exagen (Nasdaq: XGN) is a medical technology company that develops and commercializes blood tests for diagnosing, prognosing and monitoring rheumatic and autoimmune diseases, including lupus and rheumatoid arthritis. Its AVISE® portfolio serves rheumatologists and other healthcare providers, with tests designed to help distinguish diseases with overlapping symptoms and guide patient management. AVISE® CTD, its flagship test, assesses connective tissue diseases including lupus, rheumatoid arthritis and Sjögren’s syndrome; it generated 91% of revenue in 2025. The portfolio also includes tests for antiphospholipid syndrome, vasculitis, disease complications and medication monitoring. Exagen operates a specialized clinical laboratory and a sales organization focused primarily on approximately 6,000 U.S. rheumatologists. It is developing additional tests, including urinary biomarkers for lupus nephritis and assays for lupus and rheumatoid arthritis disease activity. Revenue was $66.6 million for the year ended December 31, 2025. Its website is www.exagen.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- VISTA, CA
- Fiscal year end
- December
- CIK
- 1274737
- SIC
- 8071
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Exagen Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Exagen Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Exagen Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Exagen Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Exagen Inc.'s last four quarterly filings that the numbers alone won't show?”